ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells
ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells
复制标题
DOI：
10.3109/10428194.2014.981172
复制
发表时间：
2015-07-01
影响因子：
2.6
通讯作者：
Bertino, Joseph R.
中科院分区：
文献类型：
--
作者：
Johnson-Farley, Nadine;Veliz, Jonny;Bertino, Joseph R.
双重打击淋巴瘤（DHL）是一种最近认识到的淋巴瘤，生存期不到2年。Bcl-2/Bcl-XL抑制剂ABT-737和选择性靶向Bcl-2的ABT-199均对DHL细胞系Sc-1和Ocl-LY 18、RL细胞系和原代人DHL细胞具有强效细胞毒性，但对缺乏Bcl-2表达的拉莫斯细胞没有细胞毒性。ABT-199比ABT-737更有效，是迄今为止最有前途的BH 3模拟物。DHL细胞系也敏感（
Double hit lymphoma (DHL) is a recently recognized lymphoma with a survival of less than 2 years. Both ABT-737, a Bcl-2/Bcl-XL inhibitor, and ABT-199, which selectively targets Bcl-2, were potently cytotoxic against DHL cell lines Sc-1 and Ocl-LY18, the RL cell line and primary human DHL cells, but not Ramos cells, which lack Bcl-2 expression. ABT-199 was more potent than ABT-737, and is the most promising of the BH3 mimetics to date. The DHL cell lines were also sensitive (